In order to escape immune surveillance, AML blasts downregulate major histocompatibility complex (MHC) class I and II expression (29–32) and express inhibitory ligands such as programmed death-ligand 1(PDL-1), B7-H3 (CD276), and Galectin 9 (Gal-9) (33–35). Here, CD276 is linked to acute myeloid leukemia.